
ExpreS²ion publishes video presentation

Hørsholm, Denmark, April 20, 2022 – ExpreS²ion Biotech Holding AB's affiliate ExpreS²ion Biotechnologies ApS ("ExpreS²ion") announces that a filmed company presentation by CEO Bent U. Frandsen in which he presents provides an update on ExpreS²ion's powerful platform for vaccine development, updates on the pipeline and progress towards key catalysts and the 2022 Rights Issue, is now available on the company's website.

The presentation can be found on the Company's investor website via the following link:
<https://investor.expres2ionbio.com/presentations/>

Certified Adviser

Svensk Kapitalmarknadsgranskning AB
Telefon: +46 11 32 30 732
E-post: ca@skmg.se

For further information about ExpreS²ion Biotech Holding AB, please contact:

Bent U. Frandsen, CEO
Telephone: +45 4256 6869
E-mail: buf@expres2ionbio.com

Keith Alexander, CFO
Telephone: +45 5131 8147
E-mail: ka@expres2ionbio.com

About ExpreS²ion

ExpreS²ion Biotechnologies ApS is a fully owned Danish subsidiary of ExpreS²ion Biotech Holding AB with company register number 559033-3729. ExpreS²ion has developed a unique technology platform, ExpreS², for fast and efficient non-clinical development and production of complex proteins for new vaccines and diagnostics. ExpreS² is regulatorily validated for clinical supply. The platform includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Since 2010, the Company has produced more than 500 proteins and virus-like particles (VLPs) in collaboration with leading research institutions and companies. ExpreS²ion develops novel VLP based vaccines in association with AdaptVac ApS, of which ExpreS²ion owns 34%. For additional information, please visit www.expres2ionbio.com.